Background: Glioma is a heterogeneous, highly complicated central nervous
system (CNS) tumor with uncertain mechanism of initiation and progression, resulting in
an unfavorable outcome. An extended network of cytokines is recognized as a major
regulator of glioma pathogenesis, either promoting or inhibiting glioma progression based
on their type and specificity. Interleukin-8 (IL-8) has been revealed as a critical regulator
of CNS function and development with participation in many CNS disorders including
Objective: The aim of the present review is to address the role of IL-8 in glioma pathogenesis
focusing on the implicated molecular pathways as well as on its potential targeting
for glioma therapy.
Methods and Results: PubMed-Medline, SCOPUS, and Google Scholar databases were
searched for pre-clinical and clinical studies related to IL-8 implication in gliomagenesis
and IL-8 targeting strategies for gliomas. Literature data indicate that IL-8 participates in
glioma angiogenesis and cell migration and it can serve as a potential biomarker, for early
diagnosis, follow-up and response to therapy.
Conclusion: Several promising approaches that target directly or indirectly IL-8 effects in
gliomas are currently in progress while more-in-depth studies are needed to validate its
biomarker role and elucidate the underlying molecular mechanisms.